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ABSTRACT 
 
HIV/AIDS is a major health problem in Namibia with HIV prevalence estimated at 18.2% 
among pregnant women. Antiretroviral therapy (ART) was introduced in the public sector in 
2003 and ART roll out was expanded throughout the country in the subsequent years. There are 
221 ART sites in Namibia which include 34 district hospitals and 187 outreach service points. 
Currently there are 127,486 patients registered on ART in Namibia. However, there have been 
cases of patients experiencing treatment failure. The treatment failure can give rise to the 
emergence of HIV drug resistance. Genotyping information from patients with treatment failure 
can be valuable for tracking the dominant mutations conferring HIV drug resistance. However, 
HIV genotyping is not routinely available in Namibia due to cost. It is essential to determine the 
risk factors associated with development of HIV drug resistance so that these factors can be 
addressed. The aim of the current study was to describe HIV drug resistance mutations and the 
risk factors associated with HIV drug resistance among patients failing first- line ART regimen 
in Oshikoto and Oshana regions in Namibia.  
 
The case-control study design was used to collect data from cases who were being suspected of 
treatment failure to the first–line regimen in Oshikoto and Oshana regions in Namibia. The 
demographic, clinical and genotype information was collected from patient records.  
 
Out of 168 cases, 97 cases were eligible for this study and were matched with 105 controls. The 
mean age was 44.8 (±13.2) years for controls and 43.3 (±13.3) years for cases. Cases from 
Oshana and Oshikoto regions harboured 63% and 71% respectively for nucleoside reverse 
transcriptase inhibitors mutations with the dominant mutation being M184V/I. Sixty-eight 
percent (68%) and 76% respectively harboured mutations for non-nucleoside reverse 
transcriptase inhibitors with dominant mutation being K103N. Missed appointments, initiating 
inappropriate first-line regimen and adverse events or side effects were identified as risk factors 
for virological failure with  odd ratios (OR) of 21.58 (95% CI 6.50 -71.59); 11.70 (95% CI 1.69 -
80.99) and 7.17 (95% CI 1.89 -27.22) respectively. 
 
Patients failing the first-line regimen need to be genotyped to assess the development of HIV 
drug resistance. The patients initiating ART should be educated on impacts of missing clinical 
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appointments and adverse events of the drugs in order to prevent the emergence of drug 
resistance.  
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CHAPTER 1: INTRODUCTION 
 
1.1. Background 
 
HIV/AIDS is a global health problem and all efforts are concentrating on how to combat it. The 
World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS 
(UNAIDS) launched 3x5 initiative with the strategy to put 3 million eligible people on 
antiretroviral therapy (ART) by 2005 (WHO & UNAIDS, 2003). In another effort, the 
President’s Emergency Plan for AIDS Relief was launched in 2003 to support countries which 
were heavily affected by epidemic (especially in sub-Saharan Africa, the Caribbean and Asia). 
The main strategy was to treat 2 million patients and prevent 7 million new HIV infections for 
the next five years. It was estimated that by 2010, 6.6 million adults and children in low and 
middle-income countries were put on ART (WHO, 2011). 
 
 The treatment scale up follows the public health approach of using the standardized and 
simplified treatment regimens that are consistent with international standards. The introduction 
of ART has decreased the morbidity/ mortality due to AIDS (Cavalcanti et al., 2007; Hamers et 
al., 2012).  However, it has been observed that the treatment with antiretroviral drugs can be 
accompanied by emergence of HIV drug resistance (Bennett et al., 2012; van Zyl et al., 2011; 
Hamers et al., 2012). This is due to the nature of the reverse transcriptase which is error-prone. 
The high rate of mutation can take place in the presence of drug’s selective pressure even if the 
correct regimen is used. The clinical monitoring without genotyping for HIV treatment failure 
has led to the accumulation of HIV drug resistance in resource limiting settings (van Zyl et al., 
2011; Hamers et al., 2012). This accumulation of drug resistance treatment has presented a 
challenge to the subsequent treatment for the second-line drugs that can be more toxic than first-
line drugs (Bennett et al., 2012).  
 
Since each mutation is conferred by specific drug or by specific class of drugs, several studies 
were conducted to correlate between genotyping and clinical outcome to new treatment regimen 
being initiated. Studies were conducted to determine the impact of specific nucleoside reverse 
transcriptase inhibitor drugs in treatment experienced patients when certain mutations were 
present at baseline (Izopet et al., 1999; Shulman et al., 2001; Yerly et al., 1996; Montaner et al., 
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2000; Calvez et al., 2002; Japour et al., 1995). It was found that the combination of thymidine 
analogue mutations T215Y, M41L and 210W at baseline in patients who were exposed to 
zidovudine showed poor viral load suppression when they were treated with stavudine and 
didanosine or stavudine and lamivudine. These studies showed the cross-resistance among the 
drugs that confer thymidine analogue mutations. Thus, the patients who are failing first-line 
regimen should be genotyped before initiating the second-line regimen to determine the 
combination of mutations that are present. Genotyping the patients that are failing treatment can 
give guidance on making decisions about the combination of drugs that can be used in the 
subsequent treatment. 
 
 In other studies involving didanosine in nucleoside reverse transcriptase inhibitors experienced 
patients with or without the M184V mutation at baseline showed that there was good viral load 
suppression (Sproat et al., 2005; Winters et al., 2003). The mutation, M184V, is conferred by 
nucleoside reverse transcriptase inhibitor lamivudine. These studies showed that didanosine 
continue suppressing the viruses with M184V mutation and presence of M184V does not 
preclude the use of didanosine in nucleoside reverse transcriptase inhibitor experienced patients. 
In a similar study conducted to determine virological response to etravirine in non-nucleoside 
reverse transcriptase inhibitor treatment experienced patients with K103N mutation at baseline. 
It was found that treatment with etravirine showed a good viral load suppression (Marcelin et al., 
2010). Thus, K103N did not have any effect on activity of etravirine. This study demonstrated 
that etravirine can be used in patients with mutation K103N which is conferred by nevirapine. 
 
Further studies were conducted in non-nucleoside reverse transcriptase inhibitor experienced 
patients to determine the effects of pre-existing non-nucleoside reverse transcriptase inhibitor 
mutations in response to the first-line regimen (Kuritzkes et al., 2008; Lockman et al., 2010). It 
was found that the patients with pre-existing non-nucleoside reverse transcriptase inhibitor 
mutations experienced virological failure in comparison to patients without pre-existing 
mutations. These studies demonstrated that it is vital to perform genotyping testing before 
initiation of treatment if any patient has prior exposure to ARV drugs. 
 
Summarily, the studies above have demonstrated that there is need of genotyping the patients 
who are being suspected of treatment failure of first-line regimen. This must be done before they 
are switched to the second-line regimen to avoid accumulation of HIV drug resistance. These 
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studies also prove that the selection of second-line drugs can be done based on mutation profile 
of patients to specific drugs on which they were initiated on first-line regimen. It was also shown 
that patients with prior known resistance to drugs need to be genotyped before continuing with 
subsequent treatment. 
 
Most of the genotyping data available have been on subtype B and not much information on 
non-subtype Bs (Hamers et al., 2012). Subtype B is commonly found in developed countries 
where ART first became available (Wainberg and Brenner, 2010). Due to genetic differences 
among the subtypes there are differential profiles of resistance being conferred upon exposure to 
the ARV drugs. This genetic diversity among subtypes dictates what type of resistance may arise 
and at what rate the resistance may develop or emerge. This may affect the degree of cross-
resistance within a class of ARV that may affect the treatment outcome.  
 
 In order to tackle the challenges of development of HIV drug resistance, the WHO has 
developed a global strategy for prevention and assessment of HIV drug resistance that 
recommends the monitoring of early warning indicators (Sigaloff et al., 2012; Jordan et al., 
2012). The early warning indicators can be used to assess factors that are associated with HIV 
drug resistance. The early warning indicators include:  the ARV prescribing practices, patient’s 
retention on first-line regimen at 12 months, patients lost to follow up at 12 months, on-time 
ARV drugs pick up, on-time for clinical appointment, ARV drugs supply continuity and viral 
load suppression (Jordan et al., 2012). 
 
HIV/AIDS is also a major health problem in Namibia. In 2012 HIV prevalence is estimated as 
18.2% among pregnant women (MOHSS, 2012). Antiretroviral therapy was introduced in 
Namibia in the private sector in 1997 and in the public sector in 2003. In the public sector the 
ART is provided free of charge. Since 2003, the ART roll out was expanded throughout the 
country. There are 221 ART sites in Namibia which include 34 district hospitals and 187 
outreach service points (MOHSS, 2010a). By the end of 2006 there were 33,591 individuals on 
treatment. In 2010, the Ministry of Health set the national target of achieving 95% ART 
coverage rates for eligible patients by 2015/16.  Currently there are 127,486 patients registered 
on ART in Namibia (MOHSS, 2015).   
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The current Namibian ART guidelines recommends zidovudine + lamivudine+ nevirapine, or 
stavudine + lamivudine+ nevirapine, or zidovudine + lamivudine +efavirenz,  or stavudine+ 
lamivudine+ efavirenz, or tenofovir + emtricitabine/ lamivudine+ efavirenz as the first-line ART 
regimen (MOHSS, 2010b; MOHSS, 2014). To be eligible for ART, HIV patients should have 
CD4 counts equal to or less than 350 cells/µl. After initiation on ART, patients are monitored by 
determining the viral load at six months and also in case of suspicion of treatment failure. In 
addition the CD4 is monitored every six months. In Namibia, treatment failure is defined as viral 
load more than 1000 copies/ml on two consecutive visits. The treatment failure may give rise to 
the emergence of HIV drug resistance (Bennett et al., 2012).  
 
1.2. Monitoring of early warning indicators in Namibia 
 
In 2009 Ministry of Health and Social Services in Namibia piloted five WHO early warning 
indicators from nine selected ART sites in the public sector which had electronic dispensing 
pharmacy tools (Hong et al., 2010). The early warning indicators identify the factors that affect 
the individual health facilities and programs that are potentially associated with emergence of 
HIV drug resistance. The early warning indicators abstracted were: ARV prescribing practices, 
patient’s retention on first-line regimen at 12 months, patients lost to follow up at 12 months, on-
time ARV drugs pick up and ARV drugs supply continuity. These early warning indicators were 
abstracted from patient medical and pharmacy records.   
 
The pilot study showed that all nine sites met the target of 100 % for prescribing practice of the 
appropriate first-line regimen. For patients lost to follow up at 12 months, 8 (89%) out 9 sites 
met the target of 20% or less that need to be achieved according to WHO. However it was found 
that 20.8% of patients had a period of absence without documented ART during their first year 
of treatment. For patient’s retention on first-line regimen at 12 months, it was found that 6 (67%) 
out 9 achieved a target of 0% of patients that switched to second-line regimen in 12 months 
period upon initiation. The data obtained from on-time ARV drugs pick up and drugs supply 
continuity was not satisfactory due to the patients’ medical and pharmacy records which were 
incomplete. 
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1.3. Problem statement 
 
The risk factors associated with development of HIV drug resistance are required to be identified 
at patients’ individual level in Namibia. The individual early warning indicators would enable 
the health sector in Namibia to identify the factors that can lead to emergence of HIV drug 
resistance. Since the abstraction of early warning indicators did not involve the HIV genotyping, 
based on the information obtained from early warning indicators the individual patients from 
specific sites can be genotyped. This information can be used to determine the mutations that 
confer resistance to specific drugs and their respective subtypes. Currently no data is available 
on circulating subtypes in Namibia. 
 
The emergence of HIV drug resistance presents a challenge to clinicians and ART programs as it 
requires the second-line therapy which could be costly and more toxic than first-line drugs. It is 
therefore critical to monitor patients on ART being suspected for developing drug resistance by 
genotyping (Bennett et al., 2012). Routine genotyping of patients suspected of failing treatment 
can provide information to guide clinicians for better management of patients. The Namibian 
HIV drug resistance working group believes that genotyping of patients suspected of failing 
treatment will provide valuable information (MOHSS, 2013). This information on genotyping 
can be used in decision making on maintaining the effectiveness of the first-line ART. 
Genotyping information can also be valuable data for tracking the dominant mutations 
conferring HIV drug resistance and circulating virus subtypes at the population level. This data 
is valuable because it can guide policy-makers on the selection of ART regimen for second-line 
therapy and selection of prophylaxis. This can help to ascertain the change of treatment regimen 
to more effective and durable drugs, and consequently prevent the emerging of HIV drug 
resistance.   
 
1.4. Outline of thesis 
 
 Chapter 2 covers the literature review to determine what is known about HIV drug resistance 
mutation pattern. This chapter also reviews the risk factors that contribute to emergence of HIV 
drug resistance and public health implications. 
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Chapter 3 covers the aim, objectives and methodology of the study. This chapter covers the 
study designs, the description of the population that was sampled, characteristics of the 
respondents, strategies for sampling and data collection tools. Data analysis, validity, reliability 
and ethics considerations are also covered in this chapter.  
 
Chapter 4 covers the reporting of the obtained results from the study.  
 
Chapter 5 covers the discussions of the significance of the obtained results. 
  
Chapter 6 covers the main conclusions drawn from the study. Chapter 6 also outlines the main 
recommendations that were drawn from the study. 
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CHAPTER 2: LITERATURE REVIEW 
 
2.1. Outline of literature review 
 
 This review will outline the pattern of specific HIV drug resistance mutations that are conferred 
by different classes of drugs which are used in the first-line regimen, subtype’s distribution, 
factors that contribute to emergence of HIV drug resistance and WHO global strategy to reduce 
and prevent the emergence of HIV drug resistance. 
 
Several studies that were conducted in different settings will be analysed to determine the 
frequency of mutations to the classes of antiretroviral that compose the first-line regimen.  The 
prevalence of different mutations to specific drugs will be analysed to determine the dominant 
mutations. Dominant mutations will be analysed to determine their impacts on patients’ 
management. This information can give guidance on the choice of drugs that can be used for the 
second-line regimens. 
 
The studies from literature will be analysed to determine if the information on the circulating 
subtypes is required to make decision about the classes of drugs that can be used. The studies on 
subtypes from different settings will be analysed to determine the distribution of subtypes in 
different geographical areas. The mutation patterns from different subtypes will be analysed to 
determine if they have impacts on patient treatment.  
 
 The contributing factors that could lead to emergence of HIV drug resistance such as the ARV 
drugs and regimen factors, patient factors and health systems factors will be analyzed in this 
review. The analysis of these factors can provide information to policy makers about the 
necessary interventions that need to be implemented in order to reduce the emergence of HIV 
drug resistance. These factors will be analyzed to determine how they could lead to the 
emergence of drug resistance. 
 
This review will analyze the WHO global strategy for prevention and minimizing the emergence 
of HIV drug resistance. The WHO strategy’s three elements which are: the monitoring of early 
warning indicators, surveillance of acquired HIV drug resistance in population on ART and 
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surveillance of transmitted HIV drug resistance in recently infected population will be critically 
reviewed. The strategy can be used for optimal selection of ARV drugs on population-basis and 
provides information for making program adjustments and optimize the patients’ quality care. 
 
2.2. HIV drug resistance patterns 
 
The first–line regimen is consisted of two classes of drugs: the nucleoside reverse transcriptase 
inhibitors and non-nucleoside reverse transcriptase inhibitors. These drugs target the POL gene 
that codes for reverse transcriptase enzyme. Nucleoside reverse transcriptase inhibitors drugs are 
lamivudine, emtricitabine, abacavir, didanosine, tenofovir, stavudine and zidovudine. Abacavir, 
didanosine, tenofovir, stavudine and zidovudine are regarded as thymidine analogues. Non-
nucleoside reverse transcriptase inhibitors drugs are nevirapine, efavirenz, etravirine and 
rilpivirine. The standard first-line regimen contains two nucleoside reverse transcriptase 
inhibitors and one non-nucleoside reverse transcriptase inhibitor backbone (Bennet et al., 2008, 
Jordan et al., 2012).  Even though there is standardized first–line regimen treatment with 
antiretroviral drugs it can be accompanied by emergence of HIV drug resistance (Bennett et al., 
2012; van Zyl et al., 2011; Hamers et al., 2012). The drugs become ineffective to suppress the 
HIV replication. This is due to the nature of the reverse transcriptase which is error-prone and a 
high rate of mutation can take place in presence of the drugs selective pressure even if the 
correct regimen is used. Mutations are errors that take place when reverse transcriptase is coping 
HIV genome during replication.  Each mutation is conferred by specific drug.  
 
Several studies have been conducted in different countries to determine the frequency or 
prevalence of mutations to specific antiretroviral drugs (Cavalcanti et al., 2007; van Zyl et al., 
2011; Sigaloff et al., 2012; Hamers et al., 2012; Reynolds et al., 2012). The retrospective 
description study conducted in Brazil found that nucleoside reverse transcriptase inhibitors 
mutations occurred at codon 184 (66%), while the thymidine analogue mutations such as M41L 
67N, 70R, T210W, T215F/Y and 219Q/E/N were also observed. M184V/I is mainly conferred 
by lamivudine. Thymidine analogue mutations are mainly conferred by abacavir, didanosine, 
tenofovir, stavudine and zidovudine. In non-nucleoside reverse transcriptase inhibitors the 
mutations were observed at codon 103 (62%), 190(38.7%) and 181 (29.2%) (Cavalcanti et al., 
2007). The high resistance in codon 103 for non-nucleoside reverse transcriptase inhibitors 
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mutation was due to the use of, efavirenz and nevirapine and are usually used in the first line 
regime in Brazil, while 181 occurred due to the use of nevirapine.   
 
 Studies conducted in South Africa, (van Zyl et al., 2011; Sigaloff et al., 2012) and in 13 clinical 
sites in 6 sub-Saharan African countries (Hamers et al., 2012) showed that for nucleoside 
reverse transcriptase inhibitors class, M184V was a dominant mutation followed by thymidine 
analogue mutations, K65R and Q151M. There are two types of thymidine analogue mutation 
pathways: thymidine analogue mutation-1 and thymidine analogue mutation-2. Thymidine 
analogue mutation-1 mutations included M41L and T215F/Y, while thymidine analogue 
mutation-2 mutations included D67N, K219E and K70R. The most frequent thymidine analogue 
mutation observed was D67N an indication that most patients favoured the thymidine analogue 
mutation -2 pathway (Hamers et al., 2012). Overall these studies showed that patients receiving 
containing nucleoside reverse transcriptase inhibitors for extended period have a risk of 
developing K65R, thymidine analogue mutations and Q151M mutations that can increase the 
nucleoside reverse transcriptase inhibitors broad cross-resistance which present a challenge to 
the subsequent second-line treatment (Sigaloff et al., 2012; Hamers et al., 2012). It had been 
proven that the K65R and thymidine analogue mutations conferred a cross-resistance to all 
nucleoside reverse transcriptase inhibitors except AZT (Hamers et al., 2012). These studies 
showed for non-nucleoside reverse transcriptase inhibitors class that K103N mutation was the 
most frequent followed by V106M, Y181C and G190A (van Zyl et al., 2011; Sigaloff et al., 
2012; Hamers et al., 2012). In addition it was found that patients who were on the regimen 
containing efavirenz were more likely to have K103N, V106M and P225H mutations than those 
on nevirapine containing regimen that harboured Y181C mutation (van Zyl et al., 2011). These 
results showed the cross-resistance that occurred between nevirapine and efavirenz. Thus, the 
genotyping is required to confirm that the virological failure observed is due to drug resistance 
mutations.      
 
A cohort study was conducted in Uganda to determine the pattern and frequency of nucleoside 
reverse transcriptase inhibitors resistance among patients who had showed the virological failure 
to the first-line regimen (Reynolds et al., 2012). It was found that 29 (81%) of 36 patients had 
resistance to lamivudine, and one of the participants was resistant to lamivudine at the baseline 
(Reynolds et al., 2012). This study had demonstrated that the detection of resistance among drug 
naïve patients could compromise the scaling up programs especially where the monitoring and 
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surveillance are not conducted routinely to detect the emergence of drug resistance (Reynolds et 
al., 2012). The presence of resistance in drug naïve patients can lead to the accumulation of drug 
resistance at population level if it is not detected early. 
 
2.3. Resistance and subtype diversity 
 
HIV-1 is divided into three groups: M, N and O. Group M is further sub-divided into groups 
called subtypes. Available subtypes are: A, B, C, D, F, G, H, J, K and circulating recombinant 
forms (CRF) (Peeters et al., 2013). HIV subtypes are genetically different from each other and 
can influence the drug resistance pattern (Rhee et al., 2015). Thus, in order to have an effective 
therapy the information about the circulating subtypes is required to make decision about the 
classes of drugs that can be used.  
 
Studies from different settings have shown that certain mutations are more dominant in certain 
subtypes that could have impacts on patient treatment outcome if treated with certain drugs 
(Cavalcanti et al., 2007; van Zyl et al., 2011; Hamers et al., 2012). In the study conducted in 
sub-Saharan African countries had shown that there was more K65R (17.4%) in subtype C than 
in non-subtype C (6.9%) (Hamers et al., 2012). Similar results were obtained from a study 
conducted in South Africa where it was found that patients with subtype C are more likely to 
develop mutation K65R upon exposure to stavudine or didanosine than the subtype B (van Zyl et 
al., 2011). These studies have demonstrated that prolonging exposure of patients with subtype C 
to stavudine or didanosine may develop into treatment failure due to accumulation of K65R. It 
was also shown in these studies that K65R confers broad cross-resistance to nucleoside reverse 
transcriptase inhibitors class in subtype C which is dominant in sub-Saharan Africa than in 
subtype B. These differences could be attributed to the activities of reverse transcriptase from 
subtypes C and B (Wainberg and Brenner, 2010). The mechanism was proposed to be template 
dependent (Wainberg and Brenner, 2010). In subtype C during sequence synthesis there is a stop 
at codon 65 that give rise to K65R under the drug pressure. On the other hand, in subtype B 
during the sequence synthesis there is a stop at codon 67 that gives rise to D67N and thymidine 
analogue mutations instead of K65R pathways. The K65R pathway is selected in subtype C 
when exposed to didanosine and stavudine regimen as well as the presence of Y181C in the 
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sequence. The thymidine analogue mutations are favoured whenever there is a presence of 
zidovudine containing regimen (Wainberg and Brenner, 2010). 
 
In a meta-analysis study it was showed that the T215 mutation for nucleoside reverse 
transcriptase inhibitors showed the highest proportion in subtype B (24%), while V75 mutation 
showed the highest proportion to subtype CRF01_AE (10%) (Rhee et al., 2015). The analysis 
showed that Y181C, a nucleoside reverse transcriptase inhibitor mutation, showed the highest 
proportion to subtype CRF01_AE (33%), while K103N showed the highest proportion to 
subtype B (53%). P225H showed highest proportion to CRF02_AG (14%), while V106M 
showed the highest proportion to subtype C (5%). These studies have demonstrated that some 
mutations are more specific to certain subtypes. Thus, the information about circulating subtypes 
is important to have an effective treatment. 
 
2.4. Factors contributing to HIV drug resistance and public health implications 
 
The contributing factors to the emergence of HIV drug resistance can be divided into four 
groups: the antiretroviral therapy drugs and regimen factors; virus factors; patient factors and 
programme factors (Bertagnolio et al., 2012). The analysis of these factors can provide 
information to policy makers about the necessary interventions that need to be implemented in 
order to reduce the emergence of HIV drug resistance. 
 
2.4.1. Antiretroviral drugs and regimen-related factors 
 
 WHO has recommended the use of two nucleoside reverse transcriptase inhibitors and one non-
nucleoside reverse transcriptase inhibitor in the first–line regimen (Bennett et al., 2012). 
However, it has been found that the non-nucleoside reverse transcriptase inhibitors drugs possess 
the low genetic barrier that allows the HIV to acquire high level resistance (Bertagnolio et al., 
2012). It has also been found that the regimens containing nucleoside reverse transcriptase 
inhibitors backbone can cause cross-resistance across its class. In addition the use of single dose 
of nevirapine in prevention of mother to child transmission (PMTCT) can pose high risk for 
selection of HIV drug resistance. 
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It has been shown that some drugs give rise to adverse events for patients on ART. Several 
studies conducted in different settings to assess the impacts of adverse events on treatment of 
patients initiating the first-line regimen reported a wide range of adverse events such as: 
anaemia, diarrhoea, rashes, fatigue, nausea, taste disturbances, vomiting, headache, dizziness 
and insomnia (Lartey et al., 2014; Shet et al., 2014; Marconi et al., 2013; Al-Dakkak et al., 
2013).  These studies showed that the adherence to ART was affected as a consequence of these 
adverse events. A study conducted in India on adherence of ART patients showed that the 15.5% 
of patients missed a dose due to adverse events of their ARV (Meena et al., 2014).  
 
2.4.2. Virus subtype associated factors 
 
 It has been found that the mutation patterns may differ across different subtypes; for example 
the subtype D can develop more readily HIV drug resistance than other subtypes when it is 
exposed to single dose of nevirapine (Hauser et al., 2011). A recent study conducted has 
revealed that HIV drug resistance was more common in subtype D than in subtype C among 
patients failing first-line regimen (Kyeyune et al., 2013). This treatment failure was found to be 
associated with nucleoside reverse transcriptase inhibitors treatment. It is speculated that subtype 
D has high intrinsic fitness that lead to fast disease progression. Thus, from public health point 
of view the subtype D needs stringent monitoring. In other another study conducted in South 
Africa it was revealed that mutation K65R was dominant in subtype C among patients failing 
first-line regimen containing tenofovir (Sunpath et al., 2012). Another viral factor that 
contributes to rapid emergence of HIV drug resistance is the nature of HIV reverse transcriptase 
enzyme that has high replication rate and low fidelity (Kyeyune et al., 2013). 
 
2.4.3. Patient factors 
 
Factors such as poor understanding about the disease, religious practices, higher pill burden, 
nondisclosure of HIV status and transport cost to and from the clinics, have known to result in 
poor adherence which eventually leads to the development of drug resistance (Bertagnolio et al., 
2012; Wasti et al., 2012; Falang et al., 2012; do Prado et al., 2014).  
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The level of education and knowledge about the disease can influence the success or failure of 
HIV treatment. A study conducted in Nepal showed that the patients who could not read were 
five times more likely to be non-adherent to ARV (Wasti et al., 2012). Patients may have a 
perception that ARV can only be used to treat symptoms rather than being a life-long treatment.  
Another study conducted in Nigeria showed that the patients with higher level of education had 
high adherence to ARV and showed a better knowledge of how it worked (Falang et al., 2012). 
Literate patients were able to communicate well with the health workers and remember the 
information that they were provided with.   
 
The patients’ religious practices may also influence the adherence to ARV which can lead to the 
development of HIV drug resistance. Due to personal beliefs patients may question the 
effectiveness of ARV and prefer not to visit the ART clinics. Studies had shown that some 
patients missed their doses due to religious reasons (Falang et al., 2012; Wasti et al., 2012). For 
example, for Muslims during Ramadan (the fasting festival) patients may change their routine of 
taking their drugs by missing the morning dose. 
 
A study conducted in Nigeria had shown that the patients who take three dosages daily of ARV 
were more non-adherent than the patients who take two dosages daily (Falang et al., 2012). In 
addition, patients with TB/HIV co-infection who were found to have a high pill burden and were 
more likely to default due to combination of drugs side effects and drug toxicities (do Prado et 
al., 2014). Thus, less dosages per day are more durable than a large number of drugs per day 
which can have negative impact on adherence due to side effects. 
 
The nondisclosure of HIV status to family members and friends has led to non-adherence of 
ARV since patients were subjected to discrimination. This discrimination discourages the 
patients to visit the ART clinics and only visit if nobody is seeing them. Patients develop fears of 
taking their medicines in the presence of others. Studies conducted in Nepal and Nigeria showed 
an association between disclosure and good adherence (Wasti et al., 2012; Falang et al., 2012). 
Thus, patients were taking their drugs openly without any fear of stigmatization from family 
members and friends. 
 
Studies have found that the cost of transport to the ART clinics was regarded also as a barrier to 
adherence (Falang et al., 2012; Wasti et al., 2012; Kagee et al., 2011). Unaffordability of 
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transport cost to the ART clinics discourages patients to go for drugs refill and this leads patients 
to miss dosages which can pose a risk for the development of drug resistance. 
 
2.4.4. Health system factors 
 
The health system factors such as the limited human resources, infrastructure, weak information 
system, weak monitoring and evaluation systems and a high cost for viral load monitoring can 
contribute to the emergence of HIV drug resistance (Bertagnolio et al., 2012; Colvin et al., 2014; 
Kagee et al., 2011; Wasti et al., 2012; Posse et al., 2008; Cornell et al., 2010).  
 
The shortage of staff at ART clinics can affect the service delivery to patients (Colvin et al., 
2014; Kagee et al., 2011). The task then shifts where HIV counsellors are conducting the work 
for nurses and vice versa. This is not part of their training and has generated challenges to the 
health system. As the consequence, patients may not get all the necessary attention. The staff 
shortage leads to long queues at the ART clinics and patients have to wake up early in the 
morning to queue for medication. This long waiting time at the ART clinics leads to 
overcrowding. Some patients may opt to take half doses so that the medication will last longer, 
then avoiding trips to the clinics. This situation discourages the patients to visit the clinics for 
much needed appointments.  
 
The long distance and poor infrastructure of roads have also been found to discourage patients to 
visit the ART clinics (Kagee et al., 2011; Wasti et al., 2012; Posse et al., 2008). If the roads are 
poor patients have to walk long distances to reach the clinics. A study conducted in Nepal 
showed that the patients who travelled a distance for more than one hour to the clinics were three 
times more likely to be non-adherent (Wasti et al., 2012). This could cause the patients not pick 
up their refill drugs which could lead to the development of drug resistance. 
 
Weak information system can hamper communication within and between ART clinics to 
determine patients who were still retained in care (Bertagnolio et al., 2012; Colvin et al., 2014). 
Overbooking of patients, cancelling of bookings and failure to book on time can be experienced 
if the information system for the programme is poor. These can lead patients to present to clinics 
late or miss the appointments; which eventually leads to non- adherence. When the patients do 
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not show up for the appointment there is no system to track them down and bring them back into 
care. In addition, if the ART program does not have access to death registers some deaths may 
go unreported and being documented as patients lost to follow up. The health facilities do not 
have the synchronized medical records as well as identifiers for patients so that they can be 
traced to any treatment site. The changing of treatment guidelines is also an important factor that 
can lead to ineffective treatment, especially if not communicated timeously (Colvin et al., 2014). 
The HIV treatment guidelines are continuously changing and these changes should be available 
on information system. If health workers are unaware of changes in the treatment guidelines 
patients will end up receiving ineffective care. 
 
The lack of monitoring and evaluation of system during the programme expansion had been 
found to lead to poor service delivery (Cornell et al., 2010; Bertagnolio et al., 2012). 
Unsustainability of current service care while decentralizing has been found to affect the 
performance of the health system. The demands for service care overtake the available resources 
capacity. The fund resources could be utilized for activities that were not part of the program 
priorities. A study was conducted in South Africa to determine the factors affecting program roll 
out (Cornell et al., 2010). It was found that the scale up of the program put burden on ART 
services and health information system. Thus, during expansion the monitoring of the program 
needs to be continuously evaluated.  
 
HIV viral load monitoring has been found to be a good measure for treatment failure (Hong et 
al., 2011; Bertagnolio et al., 2012). However, due to high cost, routine monitoring is limited 
which delays early detection of treatment failure. This eventually leads to the emergence of HIV 
drug resistance. Thus, viral load testing is required to monitor the progress of treatment.  
 
2.5. WHO strategy for HIV drug resistance prevention and implications for public health 
 
The scaling up of ART follows the public health approach of using the standardized and 
simplified treatment regimens that are consistent with international standards (Bennett et al., 
2012). However the treatment with ARV drugs can be accompanied by emergence and 
transmission of HIV drug resistance. The emergence of HIV drug resistance can limit the 
treatment options that will need switching to the second line regimens that is costly and can 
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produce long term toxicities (Bennett et al., 2012). In order to counter the effects of HIV drug 
resistance, WHO developed a global strategy for the prevention and minimizing the emergence 
of HIV drug resistance (Bennett et al., 2008; Bennett et al., 2012; Jordan et al., 2012). The 
WHO strategy involves three elements: the monitoring of early warning indicators, surveillance 
of acquired HIV drug resistance in population on ART and surveillance of transmitted HIV drug 
resistance in recently infected population. The results from these strategies can be used for 
optimal selection of ARV drugs on population-basis and provides information for making 
program adjustments and optimize the patients’ quality care. 
 
2.5.1. Early Warning Indicators  
 
The early warning indicators identify the factors that affect the individual health facilities to 
favor the emergence of HIV drug resistance. The timely identification of factors that negatively 
affect the health facilities helps to target the intervention that can reduce the emergence of HIV 
drug resistance (Hong et al., 2010; Hong et al., 2011; Bennett et al., 2012). Early warning 
indicators are collected from patient medical records and pharmacy records to asses ART sites 
and program factors that are potentially associated with HIV drug resistance. The results 
obtained can be used to make adjustments in order to reduce the emergence of HIV drug 
resistance to individual sites and at patients’ individual level. WHO has outlined several early 
warning indicators that should be assessed such as: ARV prescribing practices, lost to follow up 
at 12 months, retention on first-line at 12 months, on time pill pick up, on-time clinic 
appointments, drug supply continuity, viral load suppression at 12 months (Bennett et al., 2008; 
Jordan et al., 2012). 
 
ARV prescribing practices refers the percentage of patients initiating an appropriate first-line 
ART regimen which is listed in national guideline. The target should be 100%. Lost to follow up 
refers to percentage of patients who were lost to follow at 12 months upon initiation, while 
patients retention on first-line ART at 12 months refers to percentage of patients who initiated at 
ART site that are still on first-line ART regimen after 12 months and the target should be less 
than or equal to 20% and more than or equal to 70% respectively. On-time ARV drug pick up 
refers to percentage of patients  picking up all prescribed ARV drugs on time during first 12 
months and the target should be  more than or equal to 90%. ARV drug –supply continuity refers 
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to percentage of months in a year in which there was no ARV drug stock outs at the sites and the 
target should be 100%; while viral load suppression refers to percentage of patients with viral 
load less than 1000 copies/ml at 12 months and the target should be more than or equal to 70%. 
 
2.5.2. HIV drug resistance surveillance 
 
There are two surveys that are recommended by WHO: surveillance of acquired HIV drug 
resistance in population on ART and surveillance of transmitted HIV drug resistance in recently 
infected population (Bennett et al., 2008; Jordan et al., 2012). 
 
Acquired HIV drug resistance is conducted at specific health facilities to assess the performance 
in achieving the prevention of HIV drug resistance for instance maintaining the suppressed viral 
load in patients at 12 months upon initiation of ART. This survey is also used to assess the HIV 
drug resistance in patients who failed the first-line therapy. The results obtained can be used for 
programmatic adjustment where necessary. 
 
Transmitted HIV drug resistance survey assesses the recently infected individuals who become 
infected with a drug resistant HIV strain. This survey uses the sample size of 47 which is 
sampled from the first 47 patients who meet the criteria for the survey.  The prevalence for HIV 
drug resistance is classified as low (<5%), moderate (5-15%) and high (>15%) in specific 
geographic area. The results from this survey give information about selection of future first-line 
regimens and about the performance of HIV drug resistance prevention programmes. Namibia 
was classified as low (<5%) based on 2006 HIV transmitted survey (MOHSS, 2007). 
 
2.6. Summary 
 
Several studies conducted in different settings were reviewed to determine the frequency of 
mutations to the classes of antiretroviral that are composed of the first-line regimen. Studies 
showed for nucleoside reverse transcriptase inhibitors class that M184V was the most frequent 
mutation, while for non-nucleoside reverse transcriptase inhibitors class, K103N was the most 
frequent mutation. Mutation M184V was conferred due to the use of lamivudine while K103N 
was conferred due to the use of nevirapine. The information about specific mutations that are 
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being conferred by drugs can give guidance on the choice of drugs that can be used for the 
second-line regimens. 
 
Studies showed that in order to have an effective therapy the information about the circulating 
subtypes is required to make decision about the classes of drugs that can be used. HIV has 
subtypes which are genetically different from each other and can influence the drug resistance 
pattern. Studies from different settings have shown that certain mutations are more dominant in 
certain subtypes that could have impacts on patient treatment outcome. 
 
 Factors that are associated with emergence of HIV drug resistance such as the antiretroviral 
therapy drugs and regimen factors, patient factors and health systems factors were identified 
from the studies. The impact of each factor on emergence of drug resistance was analyzed. 
These factors can provide information to policy makers about the necessary interventions that 
need to be implemented in order to reduce the emergence of HIV drug resistance.  
 
The studies outlined the WHO global strategy for prevention and minimizing the emergence of 
HIV drug resistance. The WHO strategy’s three elements such as: the monitoring of early 
warning indicators, surveillance of acquired HIV drug resistance in population on ART and 
surveillance of transmitted HIV drug resistance in recently infected population were identified. 
The strategy can be used for optimal selection of ARV drugs on population-basis and provides 
information for making program adjustments and optimize the patients’ quality care. 
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CHAPTER 3: METHODOLOGY 
 
3.1. Aim and Objectives 
 
The aim of the study was to determine the risk factors leading to the development of HIV drug 
resistance mutations and to describe the dominant HIV drug resistance patterns among patients 
failing first-line antiretroviral therapy regimen in Oshikoto and Oshana regions of Namibia.  
 
The objectives of this study were as follow: 
 
1) To describe the socio-demographic and clinical profiles of patients initiated with the 
appropriate prescribed first-line regimen. 
2) To describe the profile of patients retained on first-line regimen after 6 and 12 months. 
3) To describe the profile of patients who were compliant with ART (on-time for 
appointment and no treatment interruptions).  
4) To describe HIV-1 drug resistance mutation patterns among patients failing the first-line 
antiretroviral therapy regimen. 
5) To determine the risk-factors for HIV drug resistance among patients failing the first-line 
antiretroviral therapy regimen. 
 
3.2. Study design 
 
The case-control study design was used to review the existing laboratory sequencing result 
reports from the specimens received from private and public patients suspected of treatment 
failure to first-line ART regimens between January 2008 to December 2013 in Oshikoto and 
Oshana regions in Namibia. This design was regarded as suitable for this study since the cases 
were readily available in the Namibia Institute of Pathology laboratory database. Thus, the 
information on the prevalence of laboratory confirmed HIV drug resistance mutations could be 
collected. In addition, there was no cost to retrieve the information from Namibia Institute of 
Pathology laboratory database using this study design. 
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The cases in this study were patients with treatment failure with their HIV viral loads more than 
1,000 RNA copies/ml. The controls were patients without treatment failure and their viral loads 
suppressed (less than 1,000 RNA copies/ml). The genotyped patients were regarded as cases in 
this study and their reports were available in Namibia Institute of Pathology laboratory database.  
 
3.3. Study population and sample 
 
Antiretroviral therapy was rolled out in Oshana and Oshokoto regions in the private sector in 
1997 and in the public sector in 2003. Patients access treatment at public district hospitals and 
clinics, while some patients access the treatment at private practises where private clinicians are 
available. During the clinical visits the patients were assessed for ART response. A patient was 
considered to have a treatment failure if the result of a HIV viral load test was more than 1,000 
RNA copies/ml on two consecutive visits despite undergoing intensive adherence counseling. 
The blood sample was collected from this patient and referred to Namibia Institute Pathology 
laboratory for HIV genotyping. Patients who were referred to Namibia Institute Pathology for 
genotyping between January 2008 to December 2013 from Oshana and Oshikoto regions were 
eligible for this study. Oshana and Oshikoto regions are the most densely populated and amongst 
the regions of Namibia with the highest burden on HIV infection with prevalence estimated at 
22% among pregnant women in 2012 (MOHSS, 2012). Patients from these two regions, that had 
complete HIV genotyping results information within the designated study period, were included. 
Patients with unsuccessful genotyping results were excluded from the study.  
 
By December 2013 Oshikoto region had 13,298 patients on ART, while Oshana had 13,700 
patients on ART. When the Namibia Institute of Pathology database was searched for the 
requests of HIV-1 genotyping, 266 cases were obtained from January 2008 to December 2013 
from Oshana region. While Oshikoto region only gave 28 cases. To determine odds ratio for 
developing resistance against the risk factors, a 95% confidence interval with 5% margin of 
error, a sample size of 140 patient records from Oshana region were randomly selected using 
STATA v.13 statistical analysis package (StataCorp, College Station, Texas) for review. For 
Oshikoto region all 28 patient records were selected for reviewing. This gave a total number of 
sample size of 168 cases for the study. A group of patients who initiated the treatment within the 
same period but with suppressed viral load were used as controls in this study. The controls were 
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matched with cases for sex and age which were easily available in their medical records. Out of 
140 cases selected for Oshana region, 29 cases could not be amplified, 18 cases refused consent, 
6 cases medical records were incomplete, 3 cases medical records were unavailable and in 4 
cases could not find controls. For Oshikoto region, out of 28 selected cases one (1) sample could 
not be amplified, 4 cases medical records were incomplete, and in 6 cases medical records were 
unavailable (Fig.1). For Oshana region 80 cases were successfully matched with 88 controls and 
for Oshikoto region 17 cases with complete records were matched with 17 controls. The 
combined cases from both regions gave a total number of 97 and 105 for controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flow diagram showing cases that were selected to meet the criteria 
 
138 cases with complete 
sequences 
30 cases failed amplification 
120 cases signed consent 
97 cases eligible for the study 
18 cases refused consent 
10 cases records incomplete 
9 cases records unavailable 
          4 cases could not match controls 
168 cases  
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3.4. Data collection  
3.4.1. Demographic characteristics 
 
Once the informed consent was given the participant demographic variables such as gender, age, 
marital status, employment status and place of residence were abstracted from patients’ records 
and entered into a study specific data abstraction sheet (see Appendix A). For demographic 
information the controls and cases were matched for gender and age. Depending on the 
characteristics of the cases, controls with similar demographic characteristics were selected. 
 
3.4.2. Clinical variables 
 
Participants clinical variables such as ART initiation date, WHO clinical stage at initiation, 
baseline CD4, CD4 at 6 and 12 months, ART regimen at initiation, retention on first-line 
regimen for 6 and 12 months, viral loads at 6 months and genotyping were abstracted from 
patients records and entered into a study specific data abstraction  sheet. In addition  factors such 
as self-reported adverse events or side effects, TB infection, alcohol intake, missed 
appointments, number of treatment interruption and duration on ART prior to failure were  also 
abstracted from patient’ records and entered into a study specific data abstraction sheet. The 
cases and controls were matched for ART initiation date. 
  
3.4.3. HIV resistance mutations and subtypes 
 
The genotyping information for each case was entered into a study specific data abstraction 
sheet (see Appendix A).  From each laboratory record the HIV resistance mutations for 
nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors 
were recorded. The corresponding information for the HIV-1 subtypes for protease and reverse 
transcriptase regions were also recorded on the study specific data abstraction sheet.  
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3.5. Data analysis 
 
Data entered into the paper-based data abstraction sheets were transferred into an Excel database 
during the study. After data cleaning and coding the data was transferred into STATA v.13 
statistical analysis package (StataCorp, College Station, Texas). For demographic variables, the 
proportion for cases and controls for each region, gender, age, marital status, employment status 
and place of residence as extracted from the statistical analysis package were calculated and 
tabulated.  In addition for each comparison of cases and controls the p-values were calculated 
and P values <0.05 were considered as statistically significant. 
 
In addition for clinical variables, the proportion for cases and controls for baseline CD4 (less 
than 200 or more than 200 cells/µl), CD4 at 6 and12 months were tabulated. The proportion for 
cases and controls for viral load at 6 months were recorded. The proportion of cases and controls 
for factors such as self-reported events, TB infection, alcohol intake, ART regimen at initiation, 
retention on first-line regimen at 6 and 12 months, missed appointments, and treatment 
interruptions were analyzed and reported descriptively.  
 
For analysis of prevalence of HIV-1 resistance mutations and subtypes the information were 
interpreted according to the algorithm at Stanford Sequence Resistance Database 
(http://hivdb.stanford.edu). The proportion of HIV subtypes and HIV drug resistance were 
analyzed for Oshikoto and Oshana regions.  
 
To estimate the association between different factors with HIV drug resistance the multivariate 
model including all factors with p-values less 0.232 was used to calculate unadjusted odds ratios 
(UOR) at 95% confidence interval (CI) with HIV drug resistance as the outcome variable. The 
odds ratios was adjusted (AOR) until P values <0.05 were obtained which were considered as 
statistically significant. 
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3.6. Validity and Reliability 
 
The extraction tool used to collect data from patients’ records at the health facilities and also 
from Namibia Institute of Pathology database was standardised. The samples from both sources 
were selected by using the random simple method so that there would be no selection bias and 
measurement bias would be minimal. The extraction tool was piloted at ART facilities in 
Windhoek before used in Oshikoto and Oshana regions. 
 
A different researcher collected 10% of the data from the patients’ records and laboratory 
records from Namibia Institute of Pathology database. A different researcher recorded the 
demographic, clinical, and HIV resistance mutations information from patients’ records and 
from Namibia Institute of Pathology database. Upon analysis of the collected data, results 
obtained were compared with the results that were reported in other similar studies which were 
done in different settings. 
 
3.7. Ethics considerations 
 
The consent was requested from the clinicians in charge of the health facilities to review their 
patient records. The clinicians were requested to read the information sheet that described the 
study and requested to sign the consent form. All the questions regarding the study were 
addressed accordingly. The study kept the patients personal information confidential by de-
linking patients’ identification and assigned a study number for each patient. This study did not 
inflict any harm on the subjects. The abstraction sheets with the extracted data were locked up in 
safe place where no one had access except the principal investigator. In addition the laptop that 
was used to store electronic data was password protected. Ethics clearance for this study was 
obtained from University of the Western Cape, South Africa and Ministry of Health and Social 
Services, Namibia (see Appendices B and C).  
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CHAPTER 4: RESULTS 
 
4.1. Demographic characteristics of respondents 
 
The combined data for both regions, 47 (48%) of cases were females compared to 52 (50%) in 
the control group (Table1). The mean age was 44.8 (±13.2) years for controls and 43.3 (±13.3) 
years for cases. For marital status 50 (48%) of controls were single or windowed while 59 (61%) 
of cases were single or windowed which was statistical insignificant (p<0.059). Fifty-five (52%) 
controls were married while only 38 (39%) cases were married. In addition 75(71%) controls 
and 74 (76%) cases were employed. Forty (38%) controls and 60 (62%) cases lived in urban 
areas which was statistical significant (p<0.003). 
 
4.2. Clinical characteristics of respondents 
 
The patient records reviewed did not show the WHO clinical stage at initiation of ART by 
omission or as the result of incomplete records. The controls with of CD4 more than 200 cells/µl 
at baseline, 6 and 12 months showed a proportion of 65%, 90% and 91% respectively, while 
cases had a proportion of 54%, 69% and 78% respectively (Table1). Fifty-two (54%) cases 
failed treatment before reaching 12 months on treatment. Ninety-eight (98%) of controls had 
supressed viral load at 6 months compared to 13% of cases, with the difference being statistical 
significant (p<0.001). 
 
It was found that 43 (44%) of cases had side effects or adverse events while only 26 (25%) of 
controls experienced side effects with the difference being statistical significant (p<0.003). 
Seven-teen 17 (18%) cases had TB infection while on ART and only 1 (1%) control had TB with 
the difference being statistical significant (p<0.004). Further analysis of cases with TB infection 
revealed that a proportion of 59% of males had TB infection. The results also showed that a 
proportion of 59% of cases with TB infection lived in urban areas.  The results showed that 7 
(7%) cases had used alcohol, while only 1 (1%) control had used alcohol with the difference not 
being statistical significant (p<0.056). 
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It was found that 99 (94%) and 78 (80%) had initiated first-line regimen for controls and cases 
respectively with the difference being statistical significant (p<0.009) (Table 1). The appropriate 
first-line regimens on which cases were initiated had two categories contained stavudine/ 
lamivudine/nevirapine (or efavirenz) and tenofovir/lamivudine/nevirapine (or efavirenz) with 
proportion of 13% and 3% respectively and other two categories contained 
zidovudine/lamivudine/nevirapine (or efavirenz) and tenofovir/emtricitabine/efavirenz (or 
nevirapine) with proportion of 32% each. The inappropriate first-line regimens on which cases 
were initiated had four categories contained zidovudine/lamivudine/lopinavir boosted with 
ritonavir, tenofovir/emtricitabine/aluvia, zidovudine/lamivudine/tenofovir/aluvia each with a 
proportion of 2% and zidovudine/lamivudine/aluvia with a proportion of 3%. Another ten 
categories contained lamivudine/aluvia, lamivudine/tenofovir/aluvia, aluvia/efavirenz, 
zidovudine/efavirenz, tenofovir/emtricitabine/zidovudine, zidovudine/prezista/raltegravir, 
stavudine/lamivudine/kaletra, stavudine/lamivudine, efavirenz, efavirenz/lamivudine with 
proportion of 1% each. It was found that 68 (70%) cases had missed one or more clinical 
appointments while only 11 (10%) controls had missed appointments with the difference being 
statistical significant (p<0.001). 
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Table 1 Patient characteristics by case-control status, N(%) or Mean(±SD) 
 Controls Cases p-value 
    
Region   0.800 
     Oshana 88 (84%) 80 (82%)  
     Oshikoto 17 (16%) 17 (18%)  
Sex   0.879 
     Female 52 (50%) 47 (48%)  
     Male 53 (50%) 50 (52%)  
Age(mean)(±SD) 44.8 (13.2) 43.3 (13.3) 0.071 
Marital Status   0.059 
     Single or widowed 50 (48%) 59 (61%)  
     Married  55 (52%) 38 (39%)  
Employment   0.232 
     Unemployed 30 (29%) 23 (24%)  
     Employed 75 (71%) 74 (76%)  
Residence   0.003* 
     Urban 40 (38%) 60 (62%)  
     Rural 65 (62%) 37 (38%)  
CD4 at Baseline   0.133 
     <200 cells/µl 37 (35%) 45 (46%)  
     >200 cells/µl 68 (65%) 52 (54%)  
CD4 at 6 months   0.005* 
     <200 cells/µl 11 (11%) 25 (31%)  
     >200 cells/µl 94 (90%) 56 (69%)  
CD4 at 12 months   0.069 
     <200 cells/µl 9 (9%) 10 (22%)  
     >200 cells/µl 91 (91%) 35 (78%)  
Viral Load at 6 months   <0.001* 
Suppressed  103 (98%) 13 (13%)  
Not suppressed  2 (2%) 68 (70%)  
Side effects   0.003* 
     No 79 (75%) 54 (56%)  
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     Yes 26 (25%) 43 (44%)  
TB infection   0.004* 
     No 104 (99%) 79 (82%)  
     Yes 1 (1%) 17 (18%)  
Alcohol   0.056 
     No 104 (99%) 90 (93%)  
     Yes 1 (1%) 7 (7%)  
ART regimen initiated   0.009* 
     First-line 99 (94%) 78 (80%)  
     Not First-line 6 (6%) 19 (20%)  
Missed appointments   <0.001* 
     None 94 (90%) 29 (30%)  
    Any 11 (10%) 68 (70%)  
 
*: indicates statistical significance. 
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4.3. Prevalence of HIV resistance mutations  
 
For Oshana region 50 (63%) cases harboured nucleoside reverse transcriptase inhibitors 
mutations while 30 (38%) cases did not harbour any nucleoside reverse transcriptase inhibitor 
mutation (Table 2). The dominant mutations for nucleoside reverse transcriptase inhibitor with 
corresponding proportions were M184V/I (61%), T215Y/F (28%), K65R (16%), D67N (15%), 
M41L (15%) and K70R (11%). Fifty-four (68%) cases harboured non-nucleoside reverse 
transcriptase inhibitors mutations while 26 (33%) cases did not harbour any non-nucleoside 
reverse transcriptase inhibitor mutation (Table 3). The dominant mutations with their 
corresponding proportions were K103N and Y181C with 43% and 15% respectively. These were 
followed by G190A (11%), Y188C/L (11%), V106M (10%), K101E/P (10%) and P225H (9%).  
 
For Oshikoto region 12 (71%) cases harboured nucleoside reverse transcriptase inhibitors 
mutations while 5 (29%) cases did not harbour any nucleoside reverse transcriptase inhibitor 
mutation (Table 2). The dominant mutations for nucleoside reverse transcriptase inhibitors with 
their corresponding proportions were M184V/I and T215Y/F with 47% each. These were 
followed by K70R (41%), D67N (35%), K219Q/E (29%), M41L (24%) and K65R (18%). 
Thirteen (76%) cases harboured non-nucleoside reverse transcriptase inhibitors mutations while 
4 (24%) cases did not harbour any non-nucleoside reverse transcriptase inhibitor mutation 
(Table 3). The dominant mutations with corresponding proportions were K103N and V106M 
with 41% and 24% respectively. These were followed by G190A, Y188C/L, K101E/P and 
Y181C with 18 % each. 
 
Overall a proportion of 23% cases did not show any mutation for nucleoside reverse 
transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors for both regions and 
these cases shared the same clinical risk factors with those that had mutations. For subtypes, 
Oshana region the dominant subtypes were subtypes C and 08_BC/C with proportion of 85% 
and 10% respectively. These were followed by C/31_BC, 31_BC/C, K/C and 02_AG/G with 1% 
each. For Oshikoto region the subtype C was the most dominant with proportion of 82%.  This 
was followed by 08_BC/C, B/C and 01_AE/A1 with 6% each.  
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Table 2 Prevalence of nucleoside reverse transcriptase inhibitors (NRTI) HIV-1 drug 
resistance mutations among cases who were genotyped. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NRTI Mutations Oshana 
N (%) 
Oshikoto 
N(%) 
Any NRTI mutation  50(63%) 12(71%) 
M184V/I 49(61%) 8(47%) 
D67N 12(15%) 6(35%) 
T215Y/F 22(28%) 8(47%) 
K70R 9(11%) 7(41%) 
K219Q/E 3(4%) 5(29%) 
M41L 12(15%) 4(24%) 
A62V 1(1%) - 
V75I/M 3(4%) 1(6%) 
K65R 13(16%) 3(18%) 
L74I 2(3%) - 
L210W 1(1%) 1(6%) 
E44D 3(4%) - 
T69D 5(6%) 1(6%) 
F77L 1(1%) - 
V118I 1(1%) - 
Without Mutations 30(38%) 5(29%) 
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Table 3 Prevalence of non-nucleoside reverse transcriptase inhibitors (NNRTI) HIV-1 
drug resistance mutations among cases who were genotyped. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NNRTI Mutations Oshana 
N(%) 
Oshikoto 
N(%) 
Any NNRTI mutation  54(68%) 13(76%) 
K103N 34(43%) 7(41%) 
V106M 8(10%) 4(24%) 
G190A 9(11%) 3(18%) 
Y188C/L 9(11%) 3(18%) 
K101E/P 8(10%) 3(18%) 
P225H 7(9%) - 
Y181C 12(15%) 3(18%) 
L100I 1(1%) 1(6%) 
V108I 6(8%) 1(6%) 
K238K/T 1(1%) - 
M230L 5(6%) 1(6%) 
A98G 5(6%) 1(6%) 
F227L 3(4%) 1(6%) 
V179D 2(3) - 
Without Mutations 26(33%) 4(24%) 
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4.4. The risk factors associated with HIV drug resistance 
 
Table 4 shows the association of demographic and clinical factors with HIV drug resistance as 
the outcome. Before the odd ratios were adjusted to remove the confounding factors, the results 
showed 12 potential risk factors could be associated with drug resistance from multivariate 
model. The patients who TB infection were 19 times more likely to develop HIV drug resistance 
and patients who had missed appointments (any) were 11 times more likely to develop HIV drug 
resistance. In addition the patients who had taken alcohol were 8 times more likely to develop 
drug resistance. The patients with CD4 at 6 and 12 months less than 200 cells/µl respectively 
were 5 and 7 times more likely to develop drug resistance. On the other hand, patients with CD4 
at baseline less than 200 cells/µl were 2 times more likely to develop drug resistance. Patients 
initiated inappropriate regimen were 4 times more likely to develop HIV drug resistance, while 
patients who experiencing side effects were 3 times more likely to develop HIV drug resistance. 
Marital status of being single or widowed showed a risk of two. Patients residing in urban and 
being employed were 2 times more likely to develop drug resistance. The age did not show any 
association with drug resistance. 
 
  As the study design is a matched case-control study, the conditional logistic regression was 
used for matched case-control. Multivariable conditional logistic regression models were then 
used to adjust for individual predictors or potential confounders. Variables that were pre-
determined to be independent predictors of treatment failure were considered candidate variables 
for the multivariable logistic regression model. The backward elimination to determine the final 
multivariable model was used. Variables with p<0.05 were kept in the final model.  After odd 
ratios adjustment of the model three risk factors such as side effects, initiating inappropriate 
first-line regimen and missed appointments showed an increase in odd ratios.  The results 
showed that patients who missed appointments, initiating inappropriate first-line regimen and 
experienced side effects respectively were 22, 12 and 7 times more likely to develop HIV drug 
resistance.  
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Further multivariable conditional logistic regression models were analyzed against risk factors 
and prevalent mutations for cases (M184V/I and K103N) with drug resistance as outcome. The 
risk factors gender and side effects showed the association with prevalent mutations M184V/I 
and K103N. The results showed that males were 3 times more likely to develop resistance for 
lamivudine or nevirapine. In addition those patients who developed side effects were 2 times 
more likely to develop resistance to lamivudine or nevirapine. 
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Table 4 Factors associated with HIV drug resistance 
Factor Unadjusted 
OR (95% CI) 
Adjusted  
OR (95% CI) 
Age 0.94 (0.88 to 1.01)  
Marital status (single or widowed) 1.84 (0.98 to 3.48)  
Employment (employed) 1.65 (0.73 to 3.75)  
Residence (urban) 2.38 (1.33 to 4.17)  
CD4 at baseline <200 cells/µl 1.62 (0.86 to 3.05)  
CD4 at 6 months <200 cells/µl 4.63 (1.57 to 13.70)  
CD4 at 12 months <200 cells/µl 6.99 (0.86 to 56.89)  
Side effects (yes) 2.96 (1.44 to 6.08) 7.17 (1.89 to 27.22) 
TB (yes)     18.81 (2.49 to 141.89)  
Alcohol (yes) 7.80 (0.95 to 63.91)  
 Inappropriate first-line regimen 3.73 (1.38 to 10.07) 11.70 (1.69 to 80.99) 
Missed appointments (any) 11.35 (4.90 to 26.27) 21.58 (6.50 to 71.59) 
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CHAPTER 5: DISCUSSION 
 
To the best of my knowledge this is the first study investigating the individual factors that can 
contribute to the emergence of HIV drug resistance in Namibia. The discussion will outline how 
important it is to initiate the appropriate first–line regimen for the ART. In addition the 
prevalence and profile of HIV drug resistance mutations obtained from the current study will be 
compared to the profiles obtained from other studies. The relationship between the treatment 
failure and the missing of clinical appointments will also be revealed. Adverse events that are 
experienced when the patients are subjected to ART will be outlined and how to overcome them 
in order to prevent treatment failure. The challenges that TB infection presents to the 
management of HIV will be analyzed. Finally the limitations in the current study that will pave 
the way for further research will be discussed. 
 
5.1. Appropriate first–line regimen 
 
 In the current study patients who were not initiated on the appropriate first–line regimen were 
12 times more likely to experience a virological failure.  In the current study, 20% of cases were 
not initiated on the first–line regimen as recommended by Namibia national ART guideline. 
Some cases were initiated on mono or dual therapy.  A similar study conducted in India showed 
that 58% of patients who failed the first-line regimen were not on the recommended combination 
of ARV drugs since some patients were on single and dual drugs (Gupta et al., 2010). Another 
study conducted in the United States to determine the predictors of virological failure among 
patients on ART showed that patients with prior history of ART, were two times more likely to 
experience the virological failure whenever initiated on the first-line regimen (Robbins et al., 
2010). Ding et al. (2009) also demonstrated that patients who had prior history use of mono- or 
dual therapy were 3 times more likely to have a sub-optimal virological response than if they 
would have been drug naïve. Studies were conducted to determine the effectiveness of using a 
combination of three drugs in nucleoside reverse transcriptase inhibitors treatment experienced 
patients. When zidovudine exposed patients were treated with combination of drugs 
zidovudine/lamivudine/indinavir (Gulick et al., 1997; Descamps et al., 2002). In the group that 
was treated with combination of three drugs showed good viral load suppression in comparison 
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to the group that was treated with zidovudine + lamivudine only. This is an indication how 
effective using the combination of three drugs. These studies reconfirmed what has been 
recommended by WHO. WHO guidelines recommended that 100% of patients should be 
initiated on an appropriate first–line regimen that contains two nucleoside reverse transcriptase 
inhibitors and one non-nucleoside reverse transcriptase inhibitor (Bennet et al., 2008, Jordan et 
al., 2012). Thus, the use of appropriate first-line regimen is necessary so that the long- term 
effectiveness of ART can be sustained and subsequent use of second line regimen cannot be 
compromised. Maintaining the appropriate first-line regimen can prevent the development of 
HIV drug resistance. Based on the results obtained from the current study there is a need for 
Namibia to reinforce the policy for patients to be initiated on appropriate first-line regimen in all 
settings by setting up an inspection team for each site initiating ART. 
 
5.2. Prevalence of HIV resistance mutations 
 
In the current study the most prevalent mutations for nucleoside reverse transcriptase inhibitors 
observed were M184V, T215 F/Y, K65R, D67N, M41L, K70R and K219Q/E. M184V/I is 
mainly caused by the use of lamivudine in the first-line regimen, while T215Y/F, K65R, D67N, 
M41L and K70R that are regarded as thymidine analogue mutations develop mainly due to the 
use of zidovudine, stavudine, tenofovir and abacavir which are standard first-line regimens 
(Whitcomb et al., 2003). For non-nucleoside reverse transcriptase inhibitors the dominant 
mutations were K103N, Y181C, G190A, Y188C, V106M, K101E/P and P225H. Mutations 
K101E/P, K103N, G190A, Y188C, V106M, and P225H are mainly developed due to the use of 
nevirapine and efavirenz in the first-line regimen, while Y181C is mainly caused by nevirapine 
(Cavalcanti et al., 2007; van Zyl et al., 2011; Bacheler et al. 2000). The drug resistance patterns 
obtained from the current study were similar to the patterns obtained from other studies in 
different countries such as Kenya, South Africa and China (Hassan et al., 2014; Manasa et al., 
2013; Hoffmann et al., 2013;  Xing et al., 2013; Li et al., 2013).  
 
Several studies were conducted to determine the impact of specific nucleoside reverse 
transcriptase inhibitors drugs in treatment experienced patients when certain mutations were 
present at baseline (Izopet et al., 1999; Shulman et al., 2001; Yerly et al., 1996; Montaner et al., 
2000; Calvez et al., 2002; Japour et al., 1995). It was found that the presence of combination of 
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thymidine analogue mutations T215Y, M41L and 210W at baseline in patients who were 
exposed to zidovudine showed poor viral load suppression when they were treated with 
stavudine + didanosine or stavudine + lamivudine. These studies showed the cross-resistance 
among the drugs that confer thymidine analogue mutations. Thus, the patients who are failing 
first-line regimen should be genotyped before initiating the second-line regimen to determine the 
combination of mutations that are present. Genotyping the patients that are failing treatment can 
give guidance on making decision about the alternative drugs that can be used in the subsequent 
treatment.  
 
Currently, Namibia HIV treatment guideline recommends the use of zidovudine/tenofovir/ 
lamivudine/lopinavir boosted with ritonavir or zidovudine/tenofovir/lamivudine/atazanavir 
boosted with ritonavir as the second line regimen (MOHSS, 2014). Based on the data from the 
current study for M184V/I being a dominant nucleoside reverse transcriptase inhibitor mutation 
and also showed the association with gender and side effects, is an indication that lamivudine 
should not be used in the second-line regimen. Lamivudine should be replaced with didanosine 
in the second-line regimen. In addition it has been shown that the presence of M184V mutation 
can increase susceptibility to zidovudine and tenofovir (Boyer et al., 2002). The use of 
didanosine instead of lamivudine will be effective since studies have also shown that M184V 
does not interfere with didanosine containing regimen when it is present at the baseline (Sproat 
et al., 2005; Winters et al., 2003). On the other hand for K103N being a dominant non-
nucleoside reverse transcriptase inhibitor mutation, nevirapine should be removed from the first-
line regimen since it has been widely used in PMTCT. Nevirapine should be replaced with 
etravirine since it has been shown that there was no cross-resistance between these drugs 
(Marcelin et al., 2010). 
 
The K65R mutation has been detected in the current study like in other studies conducted in HIV 
subtype C dominant areas such as; South Africa and India (Manasa et al., 2013, Hoffmann et al., 
2013; Hammer et al., 2012). It has been shown in studies that some mutations are subtype 
specific. For example a study conducted in South Africa has revealed that mutation K65R was 
dominant in subtype C among patients failing-line containing tenofovir (Sunpath et al., 2012). In 
addition it had also been shown that, there were more K103N in subtype D and subtype A than 
in subtype C. In this study there was not much diversity of subtypes that could be linked to the 
specific HIV drug resistance since the study was dominated by subtype C. The HIV drug 
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resistance profile obtained in this study can give guidance to the clinicians when making 
decisions about what drugs to use for their patients who are found to have treatment failure. 
 
5.3. Missing clinical appointments 
 
Missing more than one clinical appointment was identified in current study as one of the risk 
factors for virological failure. The current study showed that the patients who missed any 
appointment were 22 times more likely to experience the virological failure. In the current study 
it was observed that only 30% cases were on-time for appointments. Several studies in different 
settings have shown that patients who missed clinical appointments or experienced treatment 
interruptions were 2-4 times likely to develop treatment failure that eventually lead to 
development of HIV drug resistance (Ncaca et al., 2011; Kiwuwa-Muyingo et al., 2013; Fox et 
al., 2012; Robbins et al., 2010; Ndiaye et al., 2013; Arnedo et al., 2012). These studies had 
reemphasized the recommendation of WHO guidelines that recommended more than 80% on-
time for clinical appointments (Bennet et al., 2008, Jordan et al., 2012). Thus the missing 
clinical appointments should be avoided by all means to avoid treatment failure and potential 
resistance development. Based on the results obtained from the current study Namibia HIV 
treatment programs should focus on educating the patients on impact of missing appointments. 
 
5.4. Adverse events 
 
The results for adverse events obtained from the current study showed a wide range of adverse 
events which were experienced more frequently by cases than controls. There was an association 
between the presence of adverse events and virological failure. The current study showed that 
the cases with adverse events were 7 times more likely to experience the virological failure. 
Several studies were conducted in different settings to assess the impacts of adverse events on 
treatment of patients initiating the first-line regimen reported on a wide range of adverse events 
such as: anaemia, diarrhoea, rashes, fatigue, nausea, taste disturbances, vomiting, headache, 
dizziness and insomnia (Lartey et al., 2014; Shet et al., 2014; Marconi et al., 2013; Al-Dakkak 
et al., 2013).   
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The data from these studies showed that the adherence to ART was affected as consequences of 
adverse events. A study conducted in India on adherence of ART patients showed that the 15.5% 
of patients missed a dose due to side-effects of their ARV (Meena et al., 2014). A study 
conducted in South Africa showed that there was an association with fatigue, rash and low 
baseline CD4 counts with virological failure (Marconi et al., 2013).  
 
The current study and the other studies findings suggest that adverse events leading to decreased 
adherence may lead to the development of drug resistance. By knowing the adverse events can 
improve the care for patient management. This will beneficial to the programme management of 
HIV patients by educating them about the adverse events. Thus, the treatment programs need to 
put efforts on educating the patients about adverse events during counselling so that they will not 
develop poor adherence due to adverse events. 
 
5.5. TB/HIV co-infection 
 
Even after odd ratios adjustment of the model TB was excluded from the model as a 
confounding factor for virological failure, TB is a very important aspect whenever dealing with 
HIV infection. A study conducted in Israel showed that patients with TB/HIV co-infection were 
2 times more likely to develop TB multidrug resistance. This study also revealed that there were 
more deaths among patients with TB/HIV co-infection compared to patients with TB infection 
only (Zohar et al., 2014). In another study it has been shown that patients returning to TB 
treatment after defaulting were 3 times likely to develop TB/HIV co-infection and patients with 
TB/HIV co-infection were less likely to get the positive smear for TB diagnosis (do Prado et al., 
2014). For TB/HIV patients being less likely to get a positive smear warrants the use of sensitive 
screening tools for HIV positive patients for TB. In addition treating TB/HIV patients could pose 
a challenge of being a risk factor due to burden of drugs side effects and drug toxicities that 
could result in defaulting. Thus, there is a need for collaborative effort for the treatment of 
TB/HIV co-infection by evaluating the performance of TB and HIV clinics to decrease the co-
infection.  
 
Further analysis of the results for cases with TB infection revealed that males were vulnerable 
for TB/HIV co-infection. The current study also showed that there were more TB/HIV co-
infection cases in urban areas than in the rural areas. The current study results agreed with 
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results from other studies that showed that males and people living in urban areas were being at 
risk to experience TB/HIV co-infection (do Prado et al., 2014; Zohar et al., 2014; Agbor et al., 
2015).  These studies also showed that low level of education can also a risk factor for 
developing TB/HIV co-infection. However, in the current study the information on education 
level was not available in the patient records.  
 
5.6. Study Limitations 
 
Since this study concentrated on patients’ records, some selected records were not available for 
reviewing due to patients who were transferred out of health facilities or deceased. In addition 
some patients were lost to follow up after initiation of ART that led to incomplete records that 
were not usable. Due to the small size of health facilities some cases could not be matched to the 
controls. The samples that had failed amplification had affected the sample size dramatically. 
This might have been caused by transport conditions since the samples were transported to a 
South African laboratory for genotyping. Due to a large number of samples that were lost from 
the study that might have introduced bias since the sample size was reduced. In addition since 
there was no baseline genotyping information available, no evidence that the mutations detected 
in this study were acquired instead of being transmitted. In addition there was no genotyping 
information available for the controls that could shed more light about presence of mutations and 
circulation subtypes among the controls. 
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CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS 
 
6.1. Conclusions 
 
This is the first study being conducted in Namibia that investigate the risk factors that are 
associated with emergence of HIV drug resistance. The current study revealed that there are 
some ART sites that are not complying with the Namibian ART guidelines. The use appropriate 
first-line regimen is necessary so that the long- term effectiveness of ART can be sustained and 
subsequent use of second line regimen cannot be compromised. Maintaining the appropriate 
first-line regimen prevents the development of HIV drug resistance. 
 
It was deduced from this study that the missing of clinical appointments was strongly associated 
with emergence of drug resistance. The patients who missed any appointment were found to be 
22 times more likely to experience the virological failure. The missing of clinical appointments 
should be avoided by all means to avoid treatment failure and potential resistance development. 
Thus, Namibia HIV treatment programs should focus on educating the patients on impact of 
missing appointments. 
 
 The adverse events were found to be strongly associated with development of HIV drug 
resistance. This study revealed that cases with adverse events were 7 times more likely to 
experience the virological failure. By knowing the adverse events can improve the care for 
patient management. Thus, the treatment programs need to put efforts on educating the patients 
about adverse events during counselling so that they cannot develop poor adherence due to 
adverse events. Patients being initiated on the ART and TB treatment need to be monitored very 
closely because of the high burden of drugs that can lead them to missing doses due to adverse 
events. The patients should be informed about the adverse events due to interaction of ARV and 
TB drugs. During clinical visits patients should be encouraged to report any adverse event so 
that alternative drugs can be arranged. 
 
The drug resistance patterns of mutations observed in this study were similar to patterns 
observed in other studies in patients failing the first-line regimens. The current study showed 
that the dominant mutations were M184V/I and K103N for nucleoside reverse transcriptase 
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inhibitor and non-nucleoside reverse transcriptase inhibitor respectively. In addition the 
dominant mutations M184V/I and K103N showed an association against gender and side effects. 
Since M184V/I is conferred by lamivudine which is currently used in the first-line regimen and 
can also be used in the second-line regimen, this drug should not be used in the second-line 
regimen without being confirmed by genotyping. Lamivudine should be replaced with 
didanosine in the second-line regimen. Didanosine has been shown to be effective in patients 
with lamivudine resistance since does not cause any cross-resistance. On the other hand for 
K103N which is conferred by nevirapine and is widely used in PMTCT, this drug should be 
removed from the first-line regimen and be replaced with etravirine. Thus, the patients being 
initiated on the first-line regimen need to be monitored closely for development of HIV drug 
resistance that may arise. The HIV drug resistance profile obtained from monitoring can give 
guidance to the clinicians when making decisions about what drugs to use in the second line 
regimen. 
 
This study has demonstrated the importance of genotyping the patients being suspected of failing 
treatment. There were 23% of cases who did not harbor any mutation for nucleoside reverse 
transcriptase inhibitors and for non-nucleoside reverse transcriptase inhibitors for both regions 
and these cases shared the same clinical risk factors with those had mutations. If these cases 
were not genotyped and switched to second-line regimen, this would have been an unnecessary 
switch to second-line regimen. Thus, genotyping is necessary to confirm the presence of 
mutations that confer resistance before changing the regimen. In addition this study revealed the 
importance of adherence counselling, since these cases did not harbor mutation there is a 
possibility they were not adhering to treatment.  
 
6.2. Recommendations 
 
Based on the results from this study there is a need for Namibia Ministry of Health to reinforce 
the policy for patients to be initiated on appropriate first-line regimen by educating the health 
workers about importance of use the correct regimen. The ART sites should be monitored more 
closely to inspect if the patients are being initiated on the correct first-line regimen. The health 
workers should abide by Namibia HIV treatment guidelines for treatment and monitoring HIV 
patients. Currently, Namibia HIV treatment guideline recommends the use of 
 
 
 
 
  
43 
 
zidovudine/tenofovir/lamivudine/lopinavir boosted with ritonavir or 
zidovudine/tenofovir/lamivudine/atazanavir boosted with ritonavir as the second line regimen. 
Based on the data from the current study I recommend zidovudine/tenofovir/didanosine 
/lopinavir boosted with ritonavir or zidovudine/tenofovir/ didanosine /atazanavir boosted with 
ritonavir to be used as the second-line regimens. Lamivudine should be removed from the 
second-line regimen. In addition I recommend that nevirapine should be removed from the first-
line regimen and be replaced with etravirine. 
 
 In addition Namibia HIV treatment programs should focus on educating the patients on impact 
of missing appointments. The Ministry of Health should introduce a policy on default tracing of 
patients who are missing the clinical appointments. There should be a database with patients 
being initiated on ART and each patient should provide a telephone number/physical address 
where he/she can be contacted in case of missing any clinical appointment. The Ministry should 
introduce the strategies of reminding patients for their upcoming appointments. The Ministry 
should also involve more community health workers to visit patients and remind them how 
important to keep clinical appointments.  
 
The HIV patients should be educated on adverse events during counselling so that they cannot 
develop poor adherence. In addition patients should be assessed for adherence at the baseline 
and at each clinical visit. Patients should be encouraged to report adverse events so that 
alternative treatment can be arranged. HIV viral load monitoring should be used more routinely 
to monitor the patients’ adherence to treatment. 
 
Since TB is a threat to HIV patients there should be a collaborative effort for the treatment of 
TB/HIV co-infection by evaluating the performance of TB and HIV clinics. The HIV and TB 
programs need to coordinate to provide ART to TB/HIV co-infected patients and intensifying 
the TB case finding among people infected with HIV. The Ministry of Health should make it 
compulsory for HIV patients who are experiencing TB symptoms to be screened with Gene-
Xpert for TB that is widely known to be sensitive for early detection of TB. The Ministry of 
Health should make it compulsory for patients with TB/HIV co-infection to undergo direct 
observed treatment. 
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Since there were many incomplete and unavailable records in this study the ART sites need to be 
monitored regularly to assess the completeness of patients’ records. The Ministry of Health 
should reinforce the use of electronic record keeping so that information can be retrieved readily. 
 
In this study the contributing factors to the development of HIV drug resistance and dominant 
HIV drug mutations among patients failing first-line ART regimen in Oshikoto and Oshana 
regions were identified. The results from this study can give guidance on decision making about 
factors that need to be addressed for prevention of treatment failure for the patients being on the 
first-line regimen. 
 
6.3. Recommendations for further research 
 
This study has opened up questions that can be addressed through further studies. Further studies 
are required to determine the profiles of different adverse events due to the use ARV. Studies 
need to link the specific adverse events to the initiated regimen. Further studies are required to 
quantify patients’ adherence to ARV. Studies also need to be conducted to determine the number 
of missed clinical appointments that can lead to development of HIV drug resistance.  
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APPENDIX A 
Data abstraction sheet 
 
A. Demographic information 
1. Case or Control ______________ 
2. NIP requisition  number____________   
3. Study identification  number____________ 
4. Initiation date______________________ 
5. Region_________________________ 
6. Facility_________________________ 
7. Date of birth____________ 
8. Gender_______________  
9. Marital status 
a) Single 
b) Married 
c) Divorce 
d) Widow 
10. Employment status 
a) unemployed 
b) employed 
11. Place of residence 
a) urban 
b) rural 
 
B. Clinical information 
1. WHO clinical stage at initiation_________ 
2. Baseline CD4_______________ 
3.  CD4 at 6 months________________ 
4. CD4 at 12 months________________ 
5. Self-reported adverse event/side effect prior to failure___________ 
6. Any TB infection ________________ 
7. Alcohol/drug abuse recorded_________________ 
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C. Factors 
1. First line regimen at initiation___________________________ 
2. Retention on first-line regimen at 6 months___________________ 
3. Retention on first-line regimen at 12 months___________________ 
4. Missed clinical appointments prior to failure_________________ 
5. Number of treatment interruptions prior to failure __________________ 
6. Viral load at 6 months____________________ 
7. Viral load at genotyping ____________________ 
8. Duration on ARV prior to failure_______________ 
 
D. Genotyping information 
1. Genotyping year___________________ 
2. Was amplification successful? ________ 
3. Were mutations detected? _____________ 
4. Subtype________________ 
5. List of NNRTI mutations detected 
6. List of NRTI mutations detected 
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APPENDIX B 
Ethics Clearance 
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APPENDIX C 
Ethics Clearance 
 
 
 
 
 
